Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Blood (2023) 142 (Supplement 1): 182.

https://doi.org/10.1182/blood-2023-179573

Published: 2023

Journal Articles

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Boyu Hu

Blood (2023) 142 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2023-190383

Published: 2023

Journal Articles

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Robert Stuver, Esther Drill, Nivetha Ganesan, Kelsey Baron, Ellie Casper, Tiffany Chang, Sanjal H. Desai, Ayo S Falade, Natasha Galasso, Alex F. Herrera, Matthew G. Mei, Reid W. Merryman, Ivana Micallef, Harsh Shah, Alison Moskowitz

Blood (2023) 142 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2023-182143

Published: 2023

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Blood (2023) 142 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2023-182318

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Victoria A. Vardell, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2023-190719

Published: 2023

Journal Articles

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Blood (2023) 142 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2023-173470

Published: 2023

Journal Articles

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Zach Rubnitz, Victoria A. Vardell, Lindsey Fitzgerald, Allison M. Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 6169.

https://doi.org/10.1182/blood-2023-189285

Published: 2023

Journal Articles

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Daniel A. Ermann, Victoria A. Vardell, Lindsey A. Fitzgerald, Harsh Shah, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6668–6669.

https://doi.org/10.1182/blood-2022-170666

Published: 2022

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Blood (2022) 140 (Supplement 1): 9399–9401.

https://doi.org/10.1182/blood-2022-156576

Published: 2022

Journal Articles

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Victoria A. Vardell, Daniel A. Ermann, Harsh Shah, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 1085–1086.

https://doi.org/10.1182/blood-2022-169918

Published: 2022

Journal Articles

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goyal

Blood (2022) 140 (Supplement 1): 1076–1078.

https://doi.org/10.1182/blood-2022-169930

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

Journal Articles

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Natalia Neparidze, Krystal W. Lau, Xiaoliang Wang, Amy J. Davidoff, Scott F. Huntington, Omer Hassan Jamy, Gregory Calip, Harsh Shah, Deborah M. Stephens, Rebecca A. Miksad, Ravi Parikh, Samuel Takvorian, Gaurav Goyal, Erlene K Seymour

Blood (2021) 138 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2021-153787

Published: 2021

Journal Articles

Bortezomib for the Management of Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: A Scoping Review

Eric Johnson, Nicholas Lesh, Gregory Hildebrand, Harsh Shah, Afaf Osman, Mouhamed Yazan Abou-Ismail

Blood (2021) 138 (Supplement 1): 4149.

https://doi.org/10.1182/blood-2021-153437

Published: 2021

Journal Articles

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, Randa Tao, David K. Gaffney, Deborah M. Stephens, Boyu Hu

Blood (2021) 138 (Supplement 1): 49.

https://doi.org/10.1182/blood-2021-153197

Published: 2021

Journal Articles

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

Gaurav Goyal, Krystal W. Lau, Xiaoliang Wang, Amy J. Davidoff, Scott F. Huntington, Omer Hassan Jamy, Gregory Calip, Harsh Shah, Deborah M. Stephens, Rebecca A. Miksad, Ravi Parikh, Samuel Takvorian, Natalia Neparidze, Erlene K Seymour

Blood (2021) 138 (Supplement 1): 1930.

https://doi.org/10.1182/blood-2021-153625

Published: 2021

NARROW

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Bortezomib for the Management of Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: A Scoping Review

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only